Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 128,149,664
  • Shares Outstanding, K 736,450
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.15
  • Price/Sales 5.53
  • Price/Cash Flow 11.79
  • Price/Book 4.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
150.38 +15.71%
on 01/24/17
174.70 -0.39%
on 02/22/17
+21.29 (+13.94%)
since 01/23/17
3-Month
138.83 +25.34%
on 12/08/16
174.70 -0.39%
on 02/22/17
+28.98 (+19.98%)
since 11/23/16
52-Week
133.64 +30.21%
on 11/04/16
176.85 -1.61%
on 09/23/16
+26.75 (+18.17%)
since 02/23/16

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda

The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda

NFLX : 142.78 (-0.75%)
BAC : 24.58 (-0.85%)
PG : 91.13 (-0.34%)
AMGN : 174.01 (+0.81%)
HMC : 31.62 (-0.75%)
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

CELG : 119.46 (+0.16%)
SRPT : 30.15 (-0.76%)
MDCO : 51.84 (-0.73%)
BMRN : 89.29 (-0.56%)
GILD : 69.37 (+0.78%)
AMGN : 174.01 (+0.81%)
ALXN : 130.44 (-0.30%)
Lexus Extends Amgen Tour of California Partnership With Five-Year Renewal

Lexus, a returning partner of the Amgen Tour of California, has renewed its role as the official and exclusive automobile partner of the men's and women's events for the next five editions of the annual...

AMGN : 174.01 (+0.81%)
Top Research Reports for Amgen, Bank of America, and Proctor & Gamble

Top Research Reports for Amgen, Bank of America, and Proctor & Gamble

NFLX : 142.78 (-0.75%)
BAC : 24.58 (-0.85%)
MNST : 43.91 (-0.07%)
PG : 91.13 (-0.34%)
AMGN : 174.01 (+0.81%)
HMC : 31.62 (-0.75%)
Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

MYL : 42.33 (+0.79%)
RHHBY : 30.5400 (-0.23%)
AMGN : 174.01 (+0.81%)
SNSS : 4.19 (-1.41%)
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.

Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis...

AZN : 29.51 (+2.04%)
AMGN : 174.01 (+0.81%)
VRX : 16.58 (+1.41%)
CLLS : 20.78 (-5.46%)
Blog Coverage The Biologics License Application for Mylan-Biocon's Proposed Biosimilar - Pegfilgrastim, Gets Accepted by US FDA for Review

Upcoming AWS Coverage on Mallinckrodt Post-Earnings Results

MYL : 42.33 (+0.79%)
MNK : 54.47 (+0.48%)
AMGN : 174.01 (+0.81%)
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

JNJ : 121.70 (+1.82%)
ABBV : 61.94 (+0.95%)
AMGN : 174.01 (+0.81%)
PFE : 34.06 (+1.40%)
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

AZN : 29.51 (+2.04%)
JNJ : 121.70 (+1.82%)
MRK : 65.85 (+0.86%)
LLY : 82.55 (+1.83%)
NVS : 77.45 (+0.78%)
AMGN : 174.01 (+0.81%)
BIIB : 284.75 (-1.00%)
This Chart Reveals a Hidden Bull Market

This post This Chart Reveals a Hidden Bull Market appeared first on Daily Reckoning . There’s nothing quite like an earnings-driven comeback. Especially when you’re dealing with a speculative...

CELG : 119.46 (+0.16%)
XLV : 74.42 (+0.73%)
AMGN : 174.01 (+0.81%)
XBI : 67.14 (-0.96%)
BIIB : 284.75 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 175.42
1st Resistance Point 174.72
Last Price 174.01
1st Support Level 172.60
2nd Support Level 171.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.